Effect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes

Rodríguez‐Mañas, Leocadio; Lopez-Dóriga, Pedro; Petidier, Roberto; Álvarez, Marta Neira; Solı́s, Joaquı́n; Pavón, I.; Peiró, Concepción; Sánchez‐Ferrer, Carlos F.

doi:10.1097/00004872-200306000-00013

Cited by 23 publications

(14 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…None of these studies revealed abnormal responses to endothelium-independent vasodilators; in contrast, another study [67] demonstrated preserved responses to acetylcholine, but a reduced response to nitroprusside and a reduced effect of L-NMMA on basal blood flow, suggesting decreased basal release of nitric oxide. A blunted constrictor response to L-NMMA in patients with poorly controlled diabetes has also been described [64]. A blunted constrictor response to L-NMMA in patients with poorly controlled diabetes has also been described [64].…”

Section: Type 1 Diabetesmentioning

confidence: 96%

“…The data concerning endothelial function in type 1 (insulin-dependent) diabetes mellitus are conflicting, although a number of investigators have demonstrated forearm endothelial dysfunction [58][59][60][61][62][63][64]. In most studies, responses to endothelium-independent agonists were preserved, indicating decreased nitric oxide bioactivity.…”

Section: Type 1 Diabetesmentioning

confidence: 99%

See 1 more Smart Citation

Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*

Brunner

Cockcroft

Deanfield

et al. 2005

Journal of Hypertension

688

502

View full text Add to dashboard Cite

Dysfunction of the vascular endothelium is a hallmark of most conditions that are associated with atherosclerosis and is therefore held to be an early feature in atherogenesis. However, the mechanisms by which endothelial dysfunction occurs in smoking, dyslipidaemia, hyperhomocysteinaemia, diabetes mellitus, arterial hypertension, cerebrovascular diseases, coronary artery disease and heart failure are complex and heterogeneous. Recent data indicate that endothelial dysfunction is often associated with erectile dysfunction, which can precede and predict cardiovascular disease in men. This paper will provide a concise overview of the mechanisms causing endothelial dysfunction in the different cardiovascular risk factors and disease conditions, and of the impact of the intervention measures and treatments.

show abstract

Section: Type 1 Diabetesmentioning

confidence: 96%

Section: Type 1 Diabetesmentioning

confidence: 99%

Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*

Brunner

Cockcroft

Deanfield

et al. 2005

Journal of Hypertension

688

502

View full text Add to dashboard Cite

show abstract

“…A pro-oxidant and pro-inflammatory vascular environment is another characteristic of endothelial dysfunction (Félétou and Vanhoutte, 2006). Endothelial dysfunction is linked to the early development of DM in both humans and experimental animal models, and associated to reactive oxygen species (ROS) over-production (Durante et al, 1988; Calver et al, 1992; Johnstone et al, 1993; Angulo et al, 1998; Rodríguez-Mañas et al, 2003a,b). …”

Section: Il-1β Blockade and Experimental Diabetic Vasculopathymentioning

confidence: 99%

IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus

et al. 2017

Self Cite

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a chronic disease that affects nowadays millions of people worldwide. In adults, type 2 diabetes mellitus (T2DM) accounts for the majority of all diagnosed cases of diabetes. The course of the T2DM is characterized by insulin resistance and a progressive loss of β-cell mass. DM is associated with a number of related complications, among which cardiovascular complications and atherosclerosis are the main cause of morbidity and mortality in patients suffering from the disease. DM is acknowledged as a low-grade chronic inflammatory state characterized by the over-secretion of pro-inflammatory cytokines, including interleukin (IL)-1β, which reinforce inflammatory signals thus contributing to the development of complications. In this context, the pharmacological approaches to treat diabetes should not only correct hyperglycaemia, but also attenuate inflammation and prevent the development of metabolic and cardiovascular complications. Over the last years, novel biological drugs have been developed to antagonize the pathophysiological actions of IL-1β. The drugs currently used in clinical practice are anakinra, a recombinant form of the naturally occurring IL-1 receptor antagonist, the soluble decoy receptor rilonacept and the monoclonal antibodies canakinumab and gevokizumab. This review will summarize the main experimental and clinical findings obtained with pharmacological IL-1β inhibitors in the context of the cardiovascular complications of DM, and discuss the perspectives of IL-1β inhibitors as novel therapeutic tools for treating these patients.

show abstract

“…Produced by NO synthase from substrate L-arginine in vascular endothelial cells, NO acts as a potent vasodilator contributing to the regulation of vascular tone. [16][17][18] In the uremic condition, endothelial dysfunction and reduced production and effect of NO have been observed.…”

Section: Endothelin-1 and Nitric Oxide In Patients On Hemodialysismentioning

confidence: 99%

Endothelin-1 and Nitric Oxide in Patients on Chronic Hemodialysis

2008

View full text Add to dashboard Cite

Aim. To establish the role of endothelin-1 and nitric oxide in the pathogenesis of hypertension in patients on chronic aemodyalisis by correlating endothelin-1 and NO plasma concentrations to the level of arterial hypertension with respect to angiotensin-converting enzyme (ACE) inhibitor therapy. Methods. We determined plasma concentrations of endothelin-1 and NO in patients on chronic hemodialysis (CHD) before and after hemodialysis treatment. The study included 30 CHD patients and 20 healthy participants as controls. Correlation to blood pressure was determined, as well as the effect of ACE inhibitors on the relationship between both endothelin-1 and NO in correlation with arterial hypertension. Main findings. Endothelin-1 plasma concentration was significantly higher in CHD patients before hemodialysis treatment than in healthy controls. Endothelin-1 plasma concentration was also significantly higher in CHD patients after hemodialysis than in healthy controls. There was a significant decrease in endothelin-1 plasma concentration after hemodialysis in comparison with its values before hemodialysis. In CHD patients, a positive correlation was found between endothelin-1 plasma concentration and systolic blood pressure after hemodialysis, irrespective of ACE inhibitors therapy. In CHD patients taking ACE inhibitors, systolic blood pressure increased with increasing endothelin-1 plasma concentration before as well as after hemodialysis. In patients taking ACE inhibitors, there was a tendency for diastolic blood pressure to increase with an increase in endothelin-1 plasma concentration after hemodialysis and to decrease with an increase in NO plasma concentration. Conclusion. NO and endothelin-1 play a significant role in etiology of the hemodynamic changes of blood pressure during the dialysis.

show abstract

Effect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes

Abstract: In patients with diabetes type 1, glycaemic control determines the functioning of the NO system by a reversible mechanism involving superoxide anions. This finding provides an explanation of the relationship between glycaemic control and vascular complications in diabetes.

Cited by 23 publications

References 31 publications

Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*

Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension*

IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus

Endothelin-1 and Nitric Oxide in Patients on Chronic Hemodialysis

Contact Info

Product

Resources

About